Anivance AI源自陽明交通大學電機學院電機系與生醫所的團隊，自從成立於110年十二月以來，一直致力於開發創新的技術和解決方案。團隊名稱Anivance AI 由 "Animal"、"Advance" 和 "AI" 三個詞組合而成，代表著團隊的使命，而努力不僅僅局限於本地市場，拓展國際並影響全球也是未來的目標。開發一套模組化設計流程，可讓晶片設計更簡單、更可靠且成本更低。 提升五倍以上的晶片穩定性和效能，實現了更高的生物多樣性、相容性，打造更先進的微系統。

Anivance AI, founded in December 2021, is a team of passionate engineers and scientists committed to developing innovative technologies and solutions that advance animal welfare and sustainability. The name "Anivance AI" is a portmanteau of the words "animal," "advance," and "AI," reflecting the team's mission to use artificial intelligence to make a positive impact on the world. The team has developed a modular design process that simplifies, enhances reliability, and reduces costs in chip design. Achieved over five-fold improvement in chip stability and performance, enhancing biological diversity and compatibility to create advanced microsystems.

陽明賦活自本校醫學院幹細胞研究中心引進先進幹細胞及外泌體專利技術平台，以幹細胞及外泌體為主軸發展再生醫療技術，針對尚無有效治療的疾病(unmet diseases) ，例如：急性肺損傷、肝病，與醫院合作進行外泌體再生製劑臨床試驗及藥物開發，並規劃興建全國第一間PIC/S GMP 等級自動化幹細胞及外泌體生物製劑生產廠房，建立高產能、符合製藥等級之再生醫療生物製劑產品製造基地。

Yang Ming Regenerative Medical Technologies Co. leverages advanced stem cell and exosome patent platforms from the Stem Cell Research Center of our university's School of Medicine. Centered on stem cells and exosomes, the company develops regenerative therapies targeting unmet medical needs, such as acute lung injury and liver diseases, in collaboration with hospitals through clinical trials and drug development of exosome-based regenerative products. Additionally, it plans to establish Taiwan’s first PIC/S GMP-compliant automated facility for large-scale production of stem cell and exosome biopharmaceuticals, creating a high-capacity, pharmaceutical-grade manufacturing base for regenerative medicine products.

 

 

陽明寶生技之全球首研發專利能有效逆轉修復現下無藥可治癒之肺纖維化。肺纖維化不可逆又漸進式的惡化會造成呼吸衰竭導致死亡，美國FDA核准抗肺纖維化的藥物比樂舒活錠和抑肺纖僅能減緩纖維化速率，無法治癒肺纖維化。 陽明寶生技創辦人傅毓秀教授，以陽明交通大學醫學院解剖所為出發點，帶領研發團隊實現使用異體（非自身）臍帶間質幹細胞逆轉修復肺臟纖維化，並領先取得多項專利，透過新興細胞療法喚醒自體再生機制，達到修復療效。實驗證明，人類臍帶間質幹細胞其安全性及療效和成本均優於現行兩樣抗纖維化藥物以及脂肪間質幹細胞。陽明寶之細胞製劑安全性高，細胞在二十代後仍具穩定幹細胞特性，患者毋需儲存自己的臍帶，需要時可即時從細胞庫取得能逆轉修復肺纖維化的治療。

Using human umbilical stem cells, Yang Ming StemMax provides the world's first patented cell therapy for effectively reversing and repairing pulmonary fibrosis that currently has no cure. The irreversible and progressive deterioration of pulmonary fibrosis causes respiratory failure and death. The US FDA approved anti-fibrosis drugs for lungs, Pirfenidone and Nintedanib, can only slow down the rate of fibrosis but cannot cure pulmonary fibrosis. The company founder, Dr. Yu-show Fu of NYCU medical school, has achieved using allogeneic (non-autologous) human umbilical Mesenchymal Stem Cells (hUMSCs) to reverse and repair pulmonary fibrosis, and obtained multiple patents for this innovation. The breakthrough cell therapy awakens the autologous regeneration mechanism and repairs scarred lung tissues in animal studies, increasing the Oxygen Saturation (SpO2) level in rats with bleomycin-induced pulmonary fibrosis from 80% to 93%. Experiments have proven that its safety, efficacy, and cost are superior to two existing anti-fibrosis drugs and adipose-derived Mesenchymal Stem Cells (AdMSCs), which can cause severe inflammations at treatment sites. Yang Ming StemMax’s human cell therapies are highly safe and non-tumorigenic. These cells retain stable stem cell properties even after twenty generations. There is no need to store one’s own umbilical cord, when in need, immediate treatment is available from our cell bank to effectively reverse and repair pulmonary fibrosis.

思睿公司針對誘導性多能幹細胞(iPSC)技術之開發和商業化利用，目標是成為亞太第一間以 iPSC 技術開發不同細胞療法的公司。

WiseRegen aims to develop and commercialize induced pluripotent stem cell (iPSC) technology, with the goal of becoming the first company in the Asia-Pacific region to use iPSC technology to develop various cell therapies.

聯創生醫之主要產品為帶鎖髓內釘遠端螺孔定位裝置（iMET），可解決IM帶鎖髓內釘的帶鎖孔定位臨床未滿足的需求， iMET已獲得美國FDA 510(k)行銷授權(K-163037)，證實了這項創新醫療器材的安全性和有效性。

The current main product: Interlocking intramedullary nail distal screw hole positioning device (iMET), which can solve the clinical unmet needs of IM Interlocking Nail's interlocking hole positioning for the clinical Unmet needs. iMET has obtained the US FDA 510(k) marketing authorization (K-163037), confirming the safety and efficacy of this innovative medical device.

智德萬生醫以人工智慧輔助自動圈註術前與術後多時間點腦部磁振影像之腫瘤及DeepBT 腦瘤智慧精準醫療系統：沿時間軸病灶偵測與標註(Tracker)。

AItewan BioMedical Technology Inc. was founded by Distinguished Professor Wu Yu-Te of National Yang Ming Chiao Tung University (NYCU), following the execution of two National Science and Technology Council (NSTC) Taiwan Germination Program I and II. These projects focused on the use of artificial intelligence to assist in the automatic annotation of brain tumor MRI images at multiple time points both pre- and post-operation, and on the development of the DeepBT intelligent precision medicine system for brain tumors: lesion detection and annotation over time (Tracker). The company was established with the approval of NYCU's spin-off regulations for AI-based smart healthcare startups, co-founded by Distinguished Professor Wu Yu-Te and Dr. Guo Wan-Yuo.
The brain tumor detection assistance system resulting from these NSTC research projects, known as the DeepBT Detector, has been exclusively licensed to NYCU and Taipei Veterans General Hospital. The DeepBT Detector has received multiple professional awards, including the ""2022 Future Tech Award,"" the ""19th National Innovation Award - Academic Research and Innovation Award,"" and the ""National Innovation Advancement Award.""
Our company's business philosophy emphasizes the full utilization of AI technology to enhance patient care quality, reduce the workload of physicians, and achieve the goals of fast, objective, quantitative, accurate, and seamless healthcare.
AItewan BioMedical Technology will continue to collaborate with medical institutions such as NYCU, Taipei Veterans General Hospital, Taichung Veterans General Hospital, Cheng Hsin General Hospital, Shin Kong Wu Huo-Shih Memorial Hospital, and the NYCU Affiliated Hospital. Additionally, the company will form strategic alliances with various information system vendors to assist in promoting and implementing AI technology.

智宇生醫創立於2016年，是由智邦科技、富錦投資、陽明交大及大船科技共同投資的生醫公司。公司秉持「以科技造福社會、以創新呼應需求」的理念，將智邦科技的物聯網技術應用於多個場域，也盡心投入銀髮照護市場；面對人口結構進入高齡化的挑戰，智宇生醫借鑒日本高齡化社會的經驗，引進日本介護食品，旨在提升國人中高齡人口的生活品質，實現企業的核心理念。

Founded in 2016, Oenix Biotech is a collaborative effort backed by Accton Technology, Fu Hsun Investment, National Yang Ming Chiao Tung University, and Ofuna Tech.
We are dedicated to our philosophy of "TECHNOLOGY INNOVATION FOR HUMAN WELFARE." By leveraging Accton's IoT technology, we apply our solutions across various sectors, with a strong focus on the senior care market. In response to the challenges posed by an aging population, we harness Japan's expertise in elderly care to introduce specialized care food products aimed at enhancing the quality of life for middle-aged and elderly individuals in Taiwan. This commitment reflects our core mission of improving lives through innovative technology.

源榮生技以初期臨床研發以及生技醫藥技術授權為主要重點,致力成為植物新藥與新型醫療器材之先驅領導者為目標。

RGENE Biotech focuses on early-stage clinical development and the licensing of biopharmaceutical technologies, with the goal of becoming a pioneering leader in botanical new drugs and innovative medical devices.

 

陽明立方之公司的主要成員來自陽明大學基因體中心，為全台灣最早成立的基因體中心，擁有獨立的定序、晶片及生物資訊團隊，在近二十年的基因體分析服務中，累積了豐沛的經驗，並據此提出立方工作站(Cubic Station)為優化基因體分析的解決方案。

Cubic Genomics is founded by core members from the Genomics Research Center at Yang Ming University, Taiwan’s first established genomics center. With independent teams specializing in sequencing, microarrays, and bioinformatics, the company brings nearly two decades of experience in genomic analysis services. Building on this expertise, Cubic Genomics has developed the Cubic Station as an optimized solution for genomic data analysis.

進康醫電為富采控股集團旗下提供生醫光電解決方案之子公司，核心技術為整合母公司光學模組，以及技轉陽明交大趙昌博教授團隊之電路設計與演算法。延伸核心技術之檢測方案可製成無線貼片，適用於生理監控、運動器材、智慧家庭、即時檢測(POCT)等場域檢測需求。

Amengine is a biomedical optoelectronics solution provider under the Ennostar Group. Its core technology is the integration of the parent company's optical modules and the circuit design and algorithms of Professor Paul C.-P. Chao’s team at National Yang Ming Chiao Tung University. Extending the core technology allows for the production of wireless patches for physiological monitoring, sports equipment, smart home, point-of-care testing (POCT), and other applications.

鉅怡智慧股份有限公司(FaceHeart Corp.)之產品FaceHeart Vital™是一套通過 FDA 認證的完全非接觸式的生理資訊量測軟體，僅需使用一般智慧型手機或平板的鏡頭，進行40至60秒的臉部掃描，即可透過臉部偵測、數位訊號處理技術及人工智慧模型運算，量測以下六種基本生理數值：心率(Heart Rate)、血壓(Blood Pressure)、血氧(Oxygen Saturation)、呼吸率(Respiration Rate)、心率變異率(Heart Rate Variability)、心房顫動(Afib)、壓力指數(Stress Index)。(1)軟體通過FDA 510(k) NO: K223622 (心跳) (2)自建億級生醫資料庫: 取得超過1.5億筆資料庫以及超過5000位受試者。 (3)軟體開發套件(SDK)可支援不同平台與終端裝置，靈活安裝於網頁、智慧型手機、平板、電腦、機器人、醫療器材、智慧家電等不同的硬體與服務情境中。

FaceHeart Corp. improves human health through its FDA 510 (k) cleared AI-driven, video-based contactless vital signs solution, FaceHeart Vitals™, providing a simple, comfortable, and cost-effective method to help patients manage their health. With only a single camera, our cutting-edge technology measures the following vital signs: Heart Rate (HR), Blood Pressure (BP), Respiration Rate (RR), Oxygen Saturation (SpO2), Heart Rate Variability (HRV), Atrial Fibrillation (AFib), and Stress Index. (1)150M Images from >5000 Patients (2)FDA 510(k) NO: K223622 (3)Medical-Grade Accuracy (4)Supports Web & Edge Solutions.

台灣數位健康致力於智慧健康管理並專注於提供創新的數位健康解決方案。公司利用人工智慧、大數據分析等技術，開發出一系列針對個人健康管理的產品和服務，涵蓋睡眠健康、慢性病管理、居家健康檢測等多個領域。其核心產品包括AI居家睡眠健康管理平台Niceleep，協助用戶進行睡眠障礙的早期偵測與管理。未來積極擴展到更廣泛的生理信號監測領域，提升數位健康管理的應用範圍。